Phenotypes Associated with This Genotype

Genotype
MGI:5906758

• Allelic Composition: Nsmce2^tm2.1Ofc/Nsmce2^tm2.1Ofc; Ndor1^{Tg(UBC-cre/ERT2)1Ejb}/0
• Genetic Background: involves: 129S/SvEv * C57BL/6 * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:227197 )

• mice die within 1 year following tamoxifen exposure at weaning

premature aging ( J:227197 )

• tamoxifen exposure beginning at weaning results in a progressive and generalized progeroid syndrome

cellular

increased micronucleus incidence ( J:227197 )

• increased incidence of micronucleated cells in MEFs following tamoxifen treatment

• dramatic increase in micronuclei in proliferating tissues following tamoxifen treatment at weaning

abnormal mitosis ( J:227197 )

• tamoxifen exposure at E13.5 results in accumulation of mitotic cells in the thymus

elevated level of mitotic sister chromatid exchange ( J:227197 )

• sister chromatid exchanges and inter-telomeric recombination rates are increased in MEFs following tamoxifen treatmen

mitotic nondisjunction ( J:227197 )

• accumulation of intercellular DNA bridges in MEFs following tamoxifen treatment

adipose tissue

decreased total body fat amount ( J:227197 )

• following tamoxifen exposure at weaning

pigmentation

abnormal coat/hair pigmentation ( J:227197 )

• following tamoxifen exposure at weaning

abnormal skin pigmentation ( J:227197 )

• following tamoxifen exposure at weaning

digestive/alimentary system

abnormal intestinal epithelium morphology ( J:227197 )

• dramatic increase in micronuclei following tamoxifen treatment at weaning

embryo

decreased embryo size ( J:227197 )

• tamoxifen exposure at E13.5 results in intrauterine dwarfism with overall loss of cellularity particularly in some specific organs including the thymus

endocrine/exocrine glands

abnormal thymus physiology ( J:227197 )

• tamoxifen exposure at E13.5 results in accumulation of mitotic cells in the thymus

growth/size/body

decreased embryo size ( J:227197 )

• tamoxifen exposure at E13.5 results in intrauterine dwarfism with overall loss of cellularity particularly in some specific organs including the thymus

hematopoietic system

abnormal thymus physiology ( J:227197 )

• tamoxifen exposure at E13.5 results in accumulation of mitotic cells in the thymus

anemia ( J:227197 )

• progressive anemia following tamoxifen exposure at weaning

immune system

abnormal thymus physiology ( J:227197 )

• tamoxifen exposure at E13.5 results in accumulation of mitotic cells in the thymus

integument

abnormal coat/hair pigmentation ( J:227197 )

• following tamoxifen exposure at weaning

abnormal skin pigmentation ( J:227197 )

• following tamoxifen exposure at weaning

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Bloom syndrome		DOID:2717	OMIM:210900	J:227197